Virus-Free Plasmid Vector for Safe Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches face challenges in safely and effectively increasing the expression of genes involved in extracellular matrix formation, particularly due to the presence of antibiotic resistance genes and viral regulatory elements in plasmid vectors, which can lead to immune responses and reduced penetration efficiency into eukaryotic cells.
Innovation Solution
Development of gene therapy DNA vectors, such as VTvaf17, that lack antibiotic resistance genes and viral regulatory elements, allowing for the efficient expression of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, and PLOD1 genes in eukaryotic cells without integrating into the genome, ensuring safe use and enhanced penetration capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional plasmid vectors are used for gene therapy, then the therapeutic genes can be delivered to eukaryotic cells, but the vectors contain antibiotic resistance genes and viral regulatory elements that cause immune responses and reduced penetration efficiency
Solution Approach 1:
The patent removes antibiotic resistance genes and viral regulatory elements from the plasmid vector structure, retaining only the essential therapeutic gene expression functionality. This extraction of harmful elements eliminates the associated immune responses and antibiotic resistance issues while preserving the vector's ability to deliver and express therapeutic genes in eukaryotic cells.
Solution Approach 2:
The patent converts the potentially harmful presence of selection markers into a benefit by using alternative selection methods that do not rely on antibiotic resistance genes. The vector system is designed to allow selection and maintenance of therapeutic genes without requiring harmful antibiotic resistance elements, thereby transforming a harmful constraint into an opportunity for safer vector design.
2Productivity
If plasmid vectors with viral regulatory elements are used, then gene expression can be achieved, but penetration efficiency into eukaryotic cells is reduced
Solution Approach 1:
The patent extracts and removes viral regulatory elements from the plasmid vector, retaining only the minimal necessary elements for therapeutic gene expression. This reduction in vector complexity and size enhances penetration efficiency into eukaryotic cells while maintaining adequate gene expression through alternative, non-viral regulatory mechanisms.
3Ease of manufacture
If antibiotic resistance genes are included in vectors for selection, then vector production is simplified, but safety and immune response are compromised
Solution Approach 1:
The patent removes antibiotic resistance genes from the vector system and replaces them with alternative selection methods. This extraction eliminates the safety concerns associated with antibiotic resistance and immune responses while maintaining the ability to selectively produce and maintain vectors through other means such as metabolic selection or fluorescent marker systems.
Data Source
AI summary
A gene therapy DNA vector based on the VTvaf17 gene therapy DNA vector carrying a target gene selected from the group of genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 to increase the expression level of this target gene in humans and animals. Moreover, the gene therapy DNA vector VTvaf17-COL1A1 or VTvaf17-COL1A2 or VTvaf17-P4HA1 or VTvaf17-P4HA2 or VTvaf17-COL7A1 or VTvaf17-CLCA2 or VTvaf17-ELN or VTvaf17-PLOD1 has the nucleotide sequence SEQ ID NO. SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 or SEQ ID No. 6 or SEQ ID No. 7 or SEQ ID No. 8, respectively. The DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, providing the possibility of its safe use for genetic therapy in humans and animals.